These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 3520353

  • 1. Results and further perspectives of plasmocytoma chemotherapy.
    Sakalová A, Hrubisko M, Gazová S, Steruská M, Prümmerová J.
    Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
    [Abstract] [Full Text] [Related]

  • 2. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
    Steinke B, Busch FW, Stapelfeld S, Ostendorf P, Waller HD.
    Dtsch Med Wochenschr; 1984 Jun 29; 109(26):1015-9. PubMed ID: 6547386
    [Abstract] [Full Text] [Related]

  • 3. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 4. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
    Wutke K, Anger G.
    Z Gesamte Inn Med; 1983 Dec 01; 38(23):630-3. PubMed ID: 6689459
    [Abstract] [Full Text] [Related]

  • 5. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
    Scheithauer W, Cortelezzi A, Fritz E, Kührer I, Polli E, Baldini L, Ludwig H.
    J Biol Response Mod; 1989 Apr 01; 8(2):109-15. PubMed ID: 2659740
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y, Karitani Y, Tanaka I, Kobayashi T, Ohno T, Kageyama S, Katayama N, Kataoka Y, Kamio N, Ohota C.
    Rinsho Ketsueki; 1984 Sep 01; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S.
    Cancer; 2003 Jan 01; 97(1):21-9. PubMed ID: 12491501
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X, Monconduit M, Menard JF, Deshayes P, Grobois B, Tanguy A, Prevost E, Piguet H.
    Rev Rhum Mal Osteoartic; 1984 May 01; 51(5):263-7. PubMed ID: 6740189
    [Abstract] [Full Text] [Related]

  • 16. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F.
    J Clin Oncol; 1991 Mar 01; 9(3):444-8. PubMed ID: 1999714
    [Abstract] [Full Text] [Related]

  • 17. [Long-term survival in multiple myeloma].
    Sakalová A, Mikulecký M, Dedík L, Prümmerová M, Gazová S, Chabronová I, Mistrík M, Lipsic T.
    Vnitr Lek; 1994 Feb 01; 40(2):98-103. PubMed ID: 8140770
    [Abstract] [Full Text] [Related]

  • 18. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S, Writing Committee of the "Bologna 90" Clinical Trial.
    Haematologica; 2002 Sep 01; 87(9):934-42. PubMed ID: 12217805
    [Abstract] [Full Text] [Related]

  • 19. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U, Crivellari D, Carbone A, Veronesi A, Galligioni E, Trovò MG, Tumolo S, Grigoletto E.
    Cancer Treat Rep; 1982 Nov 01; 66(11):1971-3. PubMed ID: 6897205
    [Abstract] [Full Text] [Related]

  • 20. [Acute and chronic renal failure in patients with myeloma].
    Biriukova LS, Volodiaeva EB, Fetisova EV, Pivnik AV, Margolin OV.
    Ter Arkh; 1999 Nov 01; 71(7):58-64. PubMed ID: 10481869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.